-+ 0.00%
-+ 0.00%
-+ 0.00%
Aytu BioPharma swings to Q1 FY27 net loss of $3.88 million year over year
Share
Listen to the news
Aytu BioPharma swings to Q1 FY27 net loss of $3.88 million year over year
  • Aytu BioPharma swung to a $3.88 million net loss in Q1 FY27 from $1.97 million net income a year earlier.
  • Net revenue rose 7% year over year to $14.84 million.
  • EXXUA net revenue climbed 25% from Q4 FY26 to $4.9 million, while quarterly prescriptions increased 33% sequentially to 4,400.
  • Rosemont agreed to acquire Aytu for $2.70 per share in cash, valuing the transaction at approximately $56 million fully diluted.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending